Pathways for aberrant angiogenesis in pancreatic cancer

Molecular Cancer

Volumn 2, Issue , 2003, Pages

  Korc, M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BONE MORPHOGENETIC PROTEIN 2; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 5; INTERLEUKIN 8; MITOGENIC AGENT; SCATTER FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

AGGRESSIVENESS; ANGIOGENESIS; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CARCINOGENICITY; DISEASE MODEL; HUMAN; IN VIVO STUDY; MITOGENESIS; MOLECULAR BIOLOGY; NONHUMAN; NUDE MOUSE; PANCREAS ADENOCARCINOMA; PARACRINE SIGNALING; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TUMOR VASCULARIZATION;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MUS MUSCULUS;

EID: 2542471865     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-2-8     Document Type: Review

References (145)

1. Warshaw AL and Fernandez-del Castillo C Pancreatic carcinoma. N Engl J Med 1992, 326(7):455-65
2. Parker SL Cancer statistics, 1997. CA Cancer J Clin 1997, 47(1):5-27
3. Bramhall SR and Neoptolemos JP Adjuvant chemotherapy in pancreatic cancer. Int J Pancreatol 1997, 21(1):59-63
4. Abrams RA Role of radiation therapy in the management of the patient with pancreatic cancer. Oncology (Huntingt) 1996, 10(9 Suppl):13-7
5. Kuvshinoff BW and Bryer MP Treatment of resectable and locally advanced pancreatic cancer. Cancer Control 2000, 7(5):428-36
6. Korc M Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am 1998, 7(1):25-41
7. Kern SE Molecular genetic alterations in ductal pancreatic adenocarcinomas. Med Clin North Am 2000, 84(3):691-5
8. Korc M, Meltzer P and Trent J Enhanced expression of epidermal growth factor receptor correlates with alterations of chromosome 7 in human pancreatic cancer. Proc Natl Acad Sci U S A 1986, 83(14):5141-4
9. Smith JJ, Derynck R and Korc M Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc Natl Acad Sci U S A 1987, 84(21):7567-70
10. Ebert M Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 1994, 54(15):3959-62
11. Kobrin MS Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1994, 202(3):1705-9
12. Yokoyama YFH, Kobrin MS, Ebert M, Friess H, Büchler MW and Korc M Betacellulin, a member of the EGF family is overexpressed in human pancreatic cancer. Int J Oncol 1995, 7:825-829
13. Kornmann MH, Beger G and Korc M Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas 1998, 17(2):169-75
14. Kornmann M Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: evidence for autocrine and paracrine actions. Oncogene 1997, 15(12):1417-24
15. Siddiqi I Increased expression of keratinocyte growth factor in human pancreatic cancer. Biochem Biophys Res Commun 1995, 215(1):309-15
16. Ebert M Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 1995, 62(5):529-35
17. Korc M Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 1992, 90(4):1352-60
18. Yamanaka Y Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 1993, 24(10):1127-34
19. Friess H Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression. Clin Cancer Res 1995, 1(11):1413-20
20. Yamanaka Y Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993, 53(21):5289-96
21. Bergmann U Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995, 55(10):2007-11
22. Friess H Cripto, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis. Int J Cancer 1994, 56(5):668-74
23. Ebert M Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 1994, 54(22):5775-8
24. Itakura J Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 1997, 3(8):1309-16
25. Luo J Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 2001, 92(3):361-9
26. Friess H Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993, 53(12):2704-7
27. Kleeff J Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999, 116(5):1202-16
28. Kleeff J Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer 1998, 77(6):860-8
29. Bergmann U Increased expression of insulin receptor substrate-1 in human pancreatic cancer. Biochem Biophys Res Commun 1996, 220(3):886-90
30. Kobrin MS Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res 1993, 53(20):4741-4
31. Wagner M Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas 1999, 19(4):370-6
32. Lu Z Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997, 42(10):2054-63
33. Wagner M Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer 1998, 78(2):255-60
34. Yamanaka Y Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993, 13(3):565-9
35. Friess H Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993, 105(6):1846-56
36. Yokoyama MEM, Funatomi H, Friess H, Büchler MW, Johnson GR and Korc M Amphiregulin is a potent mitogen in human pancreatic cancer cells: correlation with patient survival. Int J Oncol 1995, 6:625-631
37. Wagner M Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int J Cancer 1996, 68(6):782-7
38. Matsuda K Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. Cancer Res 2002, 62(19):5611-7
39. Wagner M Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo. Gastroenterology 1998, 114(4):798-807
40. Kornmann M, Arber N and Korc M Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. J Clin Invest 1998, 101(2):344-52
41. Overholser JP Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000, 89(1):74-82
42. Bruns CJ Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000, 60(11):2926-35
43. Ferrara N Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77(7):527-43
44. Dvorak HF Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999, 237:97-132
45. Ortega N, Hutchings H and Plouet J Signal relays in the VEGF system. Front Biosci 1999, 4:D141-52
46. Houck KA The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991, 5(12):1806-14
47. Poltorak Z VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997, 272(11):7151-8
48. Park JE, Keller GA and Ferrara N The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993, 4(12):1317-26
49. Olofsson B Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci U S A 1996, 93(6):2576-81
50. Grimmond S Cloning and characterization of a novel human gene related to vascular endothelial growth factor. Genome Res 1996, 6(2):124-31
51. Joukov V A novel vascular endothelial growth factor, VEGFC, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Embo J 1996, 15(7):1751
52. Yamada Y Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 1997, 42(3):483-8
53. Meyer M A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. Embo J 1999, 18(2):363-74
54. Maglione D Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991, 88(20):9267-71
55. Ferrara N Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996, 380(6573):439-42
56. Carmeliet P Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996, 380(6573):435-9
57. Shibuya M Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001, 26(1):25-35
58. Veikkola T Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000, 60(2):203-12
59. Neufeld G Vascular endothelial growth factor (VEGF) and its receptors. Faseb J 1999, 13(1):9-22
60. Kukk E VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996, 122(12):3829-37
61. Iljin K VEGFR3 gene structure, regulatory region, and sequence polymorphisms. Faseb J 2001, 15(6):1028-36
62. Soker S Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92(6):735-45
63. Kitsukawa T Overexpression of a membrane protein, neuropilin, in chimeric mice causes anomalies in the cardiovascular system, nervous system and limbs. Development 1995, 121(12):4309-18
64. Gluzman-Poltorak Z Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165. J Biol Chem 2000, 275(38):29922
65. Fong GH Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995, 376(6535):66-70
66. Shalaby F Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376(6535):62-6
67. Takashima S Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis. Proc Natl Acad Sci U S A 2002, 99(6):3657-62
68. Hanahan D and Folkman J Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86(3):353-64
69. Fang J HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic p+henotype during early tumorigenesis. Cancer Res 2001, 61(15):5731-5
70. Giordano FJ and RS Johnson Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 2001, 11(1):35-40
71. Udagawa T Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. Faseb J 2002, 16(11):1361-70
72. Folkman J What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990, 82(1):4-6
73. Folkman J Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1(1):27-31
74. Santin AD Secretion of vascular endothelial growth factor in ovarian cancer. Eur J Gynaecol Oncol 1999, 20(3):177-81
75. Plate KH Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992, 359(6398):845-8
76. Goldman CK Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery 1997, 40(6):1269-77
77. Okada F Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci U S A 1998, 95(7):3609-14
78. Meadows KN, Bryant P and Pumiglia K Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 2001, 276(52):49289-98
79. Blancher C Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 2001, 61(19):7349-55
80. Yu JL Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002, 295(5559):1526-8
81. Shi Q Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 2001, 61(10):4143-54
82. Arora R Angiogenesis as an independent prognostic indicator in node-negative breast cancer. Anal Quant Cytol Histol 2002, 24(4):228-33
83. Sledge GW Jr Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects. Semin Oncol 2002, 29(3 Suppl 11):104-10
84. Millauer B Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994, 367(6463):576-9
85. Kong HL Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998, 9(6):823-33
86. Goldman CK Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci U S A 1998, 95(15):8795-800
87. Kim KJ Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 362(6423):841-4
88. Cheng SY Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1996, 93(16):8502-7
89. Saleh M, Stacker SA and Wilks AF Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996, 56(2):393-401
90. Pavco PA Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 2000, 6(5):2094-103
91. Fong TA SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999, 59(1):99-106
92. Witte L Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev 1998, 17(2):155-61
93. Seo Y High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 2000, 88(10):2239-45
94. Ikeda N Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 1999, 79:9-10
95. Ellis LM Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer 1998, 34(3):337-40
96. Balaz P, Friess H and Büchler MW Growth factors in pancreatic health and disease. Pancreatology 2001, 1(4):343-55
97. Itakura J Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000, 85(1):27-34
98. von Marschall Z De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 2000, 119(5):1358-72
99. Hotz HG Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 2001, 5(2):131-8
100. Tokunaga T Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line. Int J Oncol 2002, 21(5):1027-32
101. Hotz HG Specific targeting of tumor vasculature by diphtheria toxin-vascular endothelial growth factor fusion protein reduces angiogenesis and growth of pancreatic cancer. J Gastrointest Surg 2002, 6(2):159-66
102. Hoshida T Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor. Pancreas 2002, 25(2):111-21
103. Ogawa T Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther 2002, 9(8):633-40
104. Solorzano CC Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK22 an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother Radiopharm 2584, 16(5):359-70
105. Gupta VK Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002, 8(1):47-54
106. Harmey JH and Bouchier-Hayes D Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002, 24(3):280-3
107. Dias S VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002, 99(7):2532-40
108. Gerber HP VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002, 417(6892):954-8
109. Tang RF Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas 2001, 22(3):285-92
110. Saimura M Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin Cancer Res 2002, 8(10):3243-9
111. Kleeff J Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer 1999, 81(4):650-7
112. Le X Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2000, 20(11):935-46
113. Shi Q Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999, 5(11):3711-21
114. Massague J TGF-beta signal transduction. Annu Rev Biochem 1998, 67:753-91
115. Rowland-Goldsmith MA Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res 2001, 7(9):2931-40
116. Rowland-Goldsmith MA MH, Matsuda K, Idezawa T, Ralli M, Ralli S and Korc M Soluble type II transforming growth factor-b receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Therapeutics 2002, 1:161-167
117. Takeuchi Y Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. Am J Gastroenterol 1993, 88(11):1928-33
118. Kleeff J Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer. Dig Dis Sci 1999, 44(9):1793-802
119. Kleeff J and Korc M Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells. J Biol Chem 1998, 273(13):7495-500
120. Yang EY and Moses HL Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990, 111(2):731-41
121. Lambert V Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. Faseb J 2001, 15(6):1021-7
122. Andreasen PA, Egelund R and Petersen HH The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000, 57(1):25-40
123. Munger JS Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int 1997, 51(5):1376-82
124. Kojima S, Nara K and Rifkin DB Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells. J Cell Biol 1993, 121(2):439-48
125. Cantero D Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997, 75(3):388-95
126. Ishiwata T Altered expression of insulin-like growth factor II receptor in human pancreatic cancer. Pancreas 1997, 15(4):367-73
127. Elsasser HP Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells. Eur J Cell Biol 1993, 61(2):321-8
128. Haroon ZA Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. Faseb J 1999, 13(13):1787-95
129. Mishima K A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc Natl Acad Sci U S A 2000, 97(15):8484-9
130. Schwarte-Waldhoff I Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci U S A 2000, 97(17):9624-9
131. Liu D EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 2002, 1(5):445-57
132. Bancroft CC Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002, 99(4):538-48
133. Hirata A ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002, 62(9):2554-60
134. Tsuzuki Y Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation. Lab Invest 2001, 81(10):1439-51
135. Yamanaka Y Synthesis and expression of transforming growth factor beta-1, beta-2, and beta-3 in the endocrine and exocrine pancreas. Diabetes 1993, 42(5):746-56
136. Reinmuth N Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002, 82(10):1377-89
137. Reinmuth N Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002, 8(10):3259-69
138. Teraoka H Enhanced VEGF production and decreased immunogenicity induced by TGF-beta 1 promote liver metastasis of pancreatic cancer. Br J Cancer 2001, 85(4):612-7
139. Ebert MP Reduced PTEN expression in the pancreas overexpressing transforming growth factor-beta 1. Br J Cancer 2002, 86(2):257-62
140. Bergers G Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000, 2(10):737-44
141. Wen S PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci U S A 2001, 98(8):4622-7
142. Liu CD Vascular endothelial growth factor is increased in ascites from metastatic pancreatic cancer. J Surg Res 2002, 102(1):31-4
143. Niedergethmann M High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002, 25(2):122-9
144. Buchler P VEGF-RII Influences the Prognosis of Pancreatic Cancer. Ann Surg 2002, 236(6):738-49
145. Baker CH, Solorzano CC and Fidler IJ Angiogenesis and cancer metastasis: antiangiogenic therapy of human pancreatic adenocarcinoma. Int J Clin Oncol 2001, 6(2):59-65